To this end, we began by investigating the neurotrophic potential of two GLP-1R/GIPR dual agonists (Twincretin and LY329, available commercially for T2DM treatment as Tirzepatide/Mounjaro®) and a GLP-1R/GIPR/GcgR triple agonist (Triagonist) as compared to a single GLP-1R agonist, exendin-4. Here, GIPR is linked to type 2 diabetes mellitus.